iwNHL 2016: Highlights from Day 1 by Catherine Bollard
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
View expert index
View all diseases
View all trials
View all medicines
EMMA Vienna 2017
View upcoming conferences
View previous conferences
HDACs in multiple myeloma: potential benefits in maintenance phase
Enrique M. Ocio, MD, PhD, from the University Hospital of Salamanca, Spain discusses optimizing the use of histone deacetylase inhibitors…
“What does the future treatment landscape of myeloma look like? “
"Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses ongoing research for multiple myeloma (MM) and…
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France, discusses the use of double autologous transplantation in multiple myeloma…
Can venetoclax be used to treat multiple myeloma (MM)?
Philippe Moreau, MD, from the University Hospital of Nantes, Nantes, France, speaks about the potential of venetoclax in multiple myeloma…
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, discusses combination therapies for relapsed and refractory myeloma treatment…
What’s new in minimal residual disease (MRD) detection in myeloma?
Joan Bladé, MD, from Hospital Clinic, Barcelona, Spain, discusses how the response assessment in myeloma is evolving at the 2017…
Comparing continuous and fixed duration myeloma treatment with triplets and doublets
Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, speaks about a debate comparing continuous…
What do current multiple myeloma clinical trials have in common?
Xavier Leleu, MD, PhD, from the Poitiers University Hospital, Poitiers, France, gives an overview of current clinical trials in multiple…
What are the practical considerations for monoclonal antibody infusion?
Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses practical management of monoclonal antibody…
How can plasma cell leukemia be managed?
Saad Usmani, MD, FACP, from the Levine Cancer Institute, Charlotte, NC, discusses the management of the rare myeloma plasma cell…
Sign up for the latest news and videos
Is CLL curable today?
How far are we from a cure for CLL?
Mechanism of action of venetoclax (ABT-199) and its side effects
Myeloma 2016: Panel discussion on novel treatments
Highlights from the International Workshop of the German CLL Study Group